Last reviewed · How we verify
Bimatoprost Solution 2
Prostaglandin F2α analogue
Prostaglandin F2α analogue Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Bimatoprost Solution 2 |
|---|---|
| Sponsor | Allergan |
| Drug class | Prostaglandin analogue |
| Target | FP receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Bimatoprost is a synthetic prostaglandin F2α analogue that acts as an agonist to the FP receptor, leading to increased uveoscleral outflow and decreased intraocular pressure.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Eyelid skin darkening
- Eyelash growth
- Itching
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes (PHASE1)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (PHASE3)
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes. (PHASE3)
- Dose-Ranging Study of the Bimatoprost Ocular Insert (PHASE2)
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost Solution 2 CI brief — competitive landscape report
- Bimatoprost Solution 2 updates RSS · CI watch RSS
- Allergan portfolio CI